D.B. Yeates
KAER Biotherapeutics Corporation, California, United States
Keywords: aerosol therapies, combat casualties, ARDS, respiratory distress, veterans healthcare
Active military personnel and veterans must be provided with state-of-the-art treatment from trauma-induced respiratory distress such as Acute Respiratory Distress Syndrome (ARDS), Acute Lung Injury (ALI), Blast Lung Injury (BLI), and pneumonia caused by bacterial and viral lung infections. Clinical trials indicate that biophysical properties of pulmonary surfactant associated with apoproteins improved oxygen/carbon dioxide exchange when instilled in distal lungs of neonates and patients with respiratory distress. Surfactant is also listed on the CHEMM list of desired countermeasures. However, at present, insufficient surfactant mass delivered by aerosol devices fail to provide hopeful life-saving outcomes. KAER addressed this recalcitrant problem with the invention - AeroPulsR. Currently, AeroPulsR is under production for animal and human trails. AeroPulsR delivers high concentrations and masses of soft respiratory aerosols that are 10 times higher than jet nebulizers and 4 times higher than mesh nebulizers. The proprietary nozzle used in AeroPulsR readily aerosolizes surfactant, antibiotics, antibodies, and proteins with viscosities between 1 – 40 cP. AeroPulsR aerosolizes liquid agent during inspiration for drug conservation. The high dose delivered in short treatment duration improves adherence and reduces long-term critical care costs. AeroPulsR is designed for use within critical care air transport, field hospitals and clinical facilities.